A study of older adults showed that 6% had depression, with higher prevalences in certain groups, including women, those who ...

Investors appeared to have entered the new year with cautious footing, with uncertainties around future Fed rate cuts and ...

Neumora Therapeutics announced that its antidepressant candidate, navacaprant, did not meet the primary endpoint in a Phase 3 study for major depressive disorder.

The KOASTAL-1 study enrolled 383 adult patients with MDD. Navacaprant was shown to be safe and generally well-tolerated with ...

Neumora Therapeutics' lead candidate, navacaprant, failed to meet primary and secondary endpoints in its Phase 3 KOASTAL-1 ...

Watertown, Massachusetts Friday, January 3, 2025, 18:00 Hrs [IST] ...

Neumora Therapeutics (NMRA) announced results from the Phase 3 KOASTAL-1 Study of navacaprant for the treatment of major depressive disorder. The KOASTAL-1 Study is the first of three replicate Phase ...

Massachusetts, USA-based based brain disease biotech Neumora Therapeutics shares tumbled 81.4% to 1.97 after it revealed that ...

China's Health Commission aims to enhance mental health services by 2027, focusing on children and adolescents. Eli Lilly ...

Neuroscience company Neumora Therapeutics (NMRA) announced today that its experimental treatment for depression, Navacaprant, ...

Neumora Therapeutics stock collapsed Thursday after its experimental depression treatment failed in the first of three ...

China's National Health Commission plans to address gaps in mental health services from 2025-2027, focusing on youth. Eli ...